Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Indivior Plc (INDV)

Indivior Plc (INDV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,283,932
  • Shares Outstanding, K 137,880
  • Annual Sales, $ 1,188 M
  • Annual Income, $ 2,000 K
  • EBIT $ 277 M
  • EBITDA $ 306 M
  • 60-Month Beta 0.68
  • Price/Sales 3.36
  • Price/Cash Flow 16.96
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 44.38% ( +0.04%)
  • Historical Volatility 50.27%
  • IV Percentile 5%
  • IV Rank 13.22%
  • IV High 186.83% on 02/19/25
  • IV Low 22.67% on 09/05/25
  • Put/Call Vol Ratio 0.00
  • Today's Volume 23
  • Volume Avg (30-Day) 838
  • Put/Call OI Ratio 0.04
  • Today's Open Interest 25,456
  • Open Int (30-Day) 23,825

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.65
  • Number of Estimates 3
  • High Estimate 0.72
  • Low Estimate 0.53
  • Prior Year 0.32
  • Growth Rate Est. (year over year) +103.13%

Price Performance

See More
Period Period Low Period High Performance
1-Month
23.55 +29.17%
on 10/13/25
32.42 -6.17%
on 11/06/25
+6.64 (+27.92%)
since 10/10/25
3-Month
22.22 +36.90%
on 09/18/25
32.42 -6.17%
on 11/06/25
+7.58 (+33.19%)
since 08/12/25
52-Week
7.62 +299.21%
on 02/25/25
32.42 -6.17%
on 11/06/25
+20.24 (+198.82%)
since 11/12/24

Most Recent Stories

More News
Indivior Presents New Real-World Evidence at AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine

RICHMOND, Va. , Nov. 3, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) presented three new scientific posters at the Academy of Managed Care Pharmacy (AMCP) Nexus 2025 conference last week,...

INDV : 30.25 (-2.64%)
Indivior Reports Third Quarter 2025 Financial Results and Raises Full-Year 2025 Financial Guidance

RICHMOND, Va. , Oct. 30, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) today reported its financial results for the third quarter ended September 30, 2025, and provided a business update.

INDV : 30.25 (-2.64%)
Indivior to Participate in the Stifel 2025 Healthcare Conference

RICHMOND, Va. , Oct. 28, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ: INDV) today announced that it will participate in the Stifel 2025 Healthcare Conference:

INDV : 30.25 (-2.64%)
Indivior to Report Third Quarter 2025 Financial Results and Host Webcast on October 30th

RICHMOND, Va. , Oct. 16, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) today announced that it will report its third quarter 2025 financial results on Thursday, October 30, 2025, at 7:00 a.m....

INDV : 30.25 (-2.64%)
Clinical Evidence Supports Rapid SUBLOCADE® Induction as a Strategy to Improve Retention in Opioid Use Disorder Treatment

Rapid induction with SUBLOCADE® showed higher treatment retention rates compared to standard induction, particularly among fentanyl-positive participants

INDV : 30.25 (-2.64%)
Indivior Proposes New Corporate Structure to Achieve U.S. Domiciliation

RICHMOND, Va. , Oct. 1, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) (" Indivior PLC " or the " Company ") today announced that it intends to pursue a change in domicile from...

INDV : 30.25 (-2.64%)
Top 100 Stocks to Buy: Indivior Advances Into Top 50 on Momentum

In Monday’s trading, the opioid-treatment pharmaceutical company’s stock moved into the top 50 in Barchart’s Top 100 Stocks to Buy in 46th position, up 11 spots from Friday. With profits rising,...

INDV : 30.25 (-2.64%)
RBGLY : 15.4700 (-0.39%)
SNY : 52.09 (+0.77%)
Indivior to Participate in Upcoming Investor Events

RICHMOND, Va. , Aug. 20, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ: INDV) today announced that it will participate in the following investor events:

INDV : 30.25 (-2.64%)
The Street Loves This ‘Strong Buy’ Pharma Stock

Indivior (INDV) is up 90% since April and has consistently hit new highs, driven by optimism for Sublocade. INDV stock set its latest 52-week high in morning trading on Aug. 8. Technical indicators are...

MSFT : 510.22 (+0.30%)
INDV : 30.25 (-2.64%)
Best Momentum Stock to Buy for August 5th

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, August 5th:F5 FFIV: This company which provides products and services to manage Internet traffic...

INDV : 30.25 (-2.64%)
FFIV : 240.68 (+0.91%)
NVT : 111.35 (+1.61%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 70%. The market has dropped from overbought territory. Beware of a potential mean reversion.

See More Share

Business Summary

Indivior PLC operates as a specialty pharmaceutical company. It is engaged in discovering and developing medications and treatment for alcohol addiction, opioid overdose, cocaine intoxication and co-occurring conditions, such as schizophrenia. The Company markets and promotes SUBOXONE (buprenorphine...

See More

Key Turning Points

3rd Resistance Point 32.15
2nd Resistance Point 31.65
1st Resistance Point 31.36
Last Price 30.25
1st Support Level 30.57
2nd Support Level 30.07
3rd Support Level 29.78

See More

52-Week High 32.42
Last Price 30.25
Fibonacci 61.8% 22.95
Fibonacci 50% 20.02
Fibonacci 38.2% 17.09
52-Week Low 7.62

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar